# Real-World Evidence on the Cardiovascular Safety of CONTRAVE® in the United States (U.S.)

> **NCT06090461** · — · COMPLETED · sponsor: **Currax Pharmaceuticals** · enrollment: 31889 (actual)

## Conditions studied

- Obesity

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06090461
- **Lead sponsor:** Currax Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2014-09
- **Primary completion:** 2022-12
- **Final completion:** 2022-12
- **Target enrollment:** 31889 (ACTUAL)
- **Last updated:** 2025-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06090461

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06090461, "Real-World Evidence on the Cardiovascular Safety of CONTRAVE® in the United States (U.S.)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06090461. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*